Crinetics Pharmaceuticals... (CRNX)
NASDAQ: CRNX
· Real-Time Price · USD
40.86
-0.65 (-1.57%)
At close: Oct 03, 2025, 3:59 PM
41.00
0.34%
After-hours: Oct 03, 2025, 07:41 PM EDT
-1.57% (1D)
| Bid | 30.15 |
| Market Cap | 3.85B |
| Revenue (ttm) | 1.39M |
| Net Income (ttm) | -369.83M |
| EPS (ttm) | -4.1 |
| PE Ratio (ttm) | -9.97 |
| Forward PE | -8.29 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 52.21 |
| Volume | 1,374,661 |
| Avg. Volume (20D) | 1,287,196 |
| Open | 41.72 |
| Previous Close | 41.51 |
| Day's Range | 40.33 - 42.01 |
| 52-Week Range | 24.10 - 62.53 |
| Beta | 0.33 |
| Ex-Dividend Date | n/a |
About CRNX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CRNX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CRNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsCrinetics Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 11, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+27.92%
Crinetics Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
1 month ago
-3.69%
CRNX stock has given up its prior gain. Crinetics Pharmaceuticals shares were trading higher after the company reported a Q2 revenue beat and announced the Palsonify NDA is on track.
1 month ago · seekingalpha.com
Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call TranscriptCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Alan S. Krasner - Corporate Participant Chief Endocrinologist - Corporate...
1 month ago · fool.com
Crinetics (CRNX) Q2 Revenue Jumps 150%Crinetics (CRNX) Q2 Revenue Jumps 150%
